Literature DB >> 3956050

Salivary antipyrine half-life during injectable progestagen contraception.

J V Joshi, K C Gupta, K T Hazari, J Gokral, S Pohujani, R Satoskar.   

Abstract

Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to 14 months were compared with values obtained in 14 non-users. Antipyrine was measured in saliva using a spectrophotometric method, following an oral dose of 18 mg/kg bodyweight. In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection. The mean antipyrine half-life in the 5 long term users of injectable progestagen was 14.21 +/- 2.53 hours compared with 13.66 +/- 0.98 hours in non-users. The results of this study suggest that - in contrast to published data on combined oral contraceptives - neither short nor long term use of parenteral norethisterone enanthate in Indian women is associated with significant alterations in antipyrine clearance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3956050     DOI: 10.2165/00003088-198611020-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  18 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

3.  Metabolism of drugs and carcinogens in man: antipyrine elimination as an indicator.

Authors:  R Kalamegham; K Krishnaswamy; S Krishnamurthy; R N Bhargava
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

4.  Effect of contraceptive agents on drug metabolism.

Authors:  A Jori; A Bianchetti; P E Prestini
Journal:  Eur J Pharmacol       Date:  1969-08       Impact factor: 4.432

5.  Impairment of antipyrine metabolism by low-dose oral contraceptive steroids.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

6.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

7.  Antipyrine half-life and drug elimination.

Authors:  A Breckenridge
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

8.  Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.

Authors:  M W Teunissen; A K Srivastava; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

9.  Inhibition of hepatic drug metabolism by norethindrone.

Authors:  B Field; C Lu; G W Hepner
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

10.  Impaired elimination of caffeine by oral contraceptive steroids.

Authors:  R V Patwardhan; P V Desmond; R F Johnson; S Schenker
Journal:  J Lab Clin Med       Date:  1980-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.